Dr. Reddy’s Laboratories informs about updates
In reference to intimation dated December 12, 2025, wherein the company had informed regarding a GMP and a Pre-Approval Inspection (PAI) conducted by the United States Food & Drug Administration (USFDA) at its formulations manufacturing facility (FTO-SEZ PU01) in Srikakulam, Andhra Pradesh, Dr. Reddy’s Laboratories has informed that the Company has received the Establishment Inspection Report (EIR) on March 04, 2026. The USFDA has classified the inspection outcome as 'Voluntary Action Indicated (VAI)' and concluded that the inspection is officially closed under 21 CFR 20.64(d)(3).
The above information is a part of company’s filings submitted to BSE.
